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ess: kwttsang@hkucc.hSummary Bronchiectasis is a chronic inflammatory and infective airway disease
characterized by irreversible dilatation of the bronchi and persistent purulent
sputum. Transforming growth factor-b1 (TGF-b1) has been found to be increased in
the lungs or bronchoalveolar lavage fluid of patients with inflammatory lung
diseases. However, little is known on the serum TGF-b1 levels in patients with
bronchiectasis. We aimed to determine the serum TGF-b1 concentrations in 95
patients with stable bronchiectasis (63 women; mean7SD age, 58.9714.1 years)
and 68 control subjects (23 women; 48.9712.8 years) by ELISA, and to correlate
with clinical parameters. The serum TGF-b1 levels were significantly higher in
bronchiectatic patients compared with control subjects (median [range], 1812.5 pg/
ml [1226.4–4114.5 pg/ml] vs. 1342.4 pg/ml [940.3–2371.7 pg/ml]; Po0:001). There
was, however, no correlation between serum TGF-b1 levels with FEV1 (% predicted),
FVC (% predicted), 24 h sputum volume, the number of bronchiectatic lung lobes or
total white blood cell count (P40:05). Our findings support previous indications that
TGF-b1 may contribute to bronchiectatic airway inflammation. Further studies on
the potential mechanisms and pathogenesis implications of this elevation should also
be pursued in future.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Bronchiectasis is a chronic infective and inflamma-
tory airway disease with diverse aetiology that is
very common among the Chinese, and is character-
ized by irreversible dilation of the bronchi and
persistent purulent sputum production. High levels
of proinflammatory cytokines are present in airway
secretions, and neutrophils are the predominate
cells in the airway lumen.1 In patients with
bronchiectasis, bronchial damage is thought to
exist due to neutrophil inflammatory products
released in response to bacterial infection.2
Chronic colonization with Pseudomonas aeruginosa
(PA) is associated with extensive lung disease and
severe airflow obstruction.3
The mechanisms underlying airway inflammation
in bronchiectasis are unknown. In other chronic
inflammatory diseases, the generation and release
of potent growth and activating factors for fibro-
blasts is particularly important. Transforming
growth factor b (TGF-b) has emerged as one of
the mediators, which have been implicated in
repair following lung injury. The mammalian TGF-
b family comprises three main isoforms designated
as TGF-b1, TGF-b2, and TGF-b3.
4 TGF-b1 is one of
the most profibrotic growth factors and has been
implicated in formation of extracellular matrix in
pulmonary fibrosis.5 Animal studies have shown
that TGF-b1 has an inhibitory effect on immunoglo-
bulin synthesis by lymphocytes and can suppress
airway inflammation.6,7 TGF-b1 levels have been
reported to be either an increase or no change in
bronchoalveolar lavage (BAL) fluid, bronchial
biopsy specimens and plasma from patients with
fibrotic lung disease, asthma and chronic obstruc-
tive pulmonary disease (COPD).8–13 To our knowl-
edge, however, there have been no previous
reports regarding serum levels of TGF-b1 in stable
bronchiectasis. Clinicopathologic correlation of
systemic TGF-b1 is also unknown in patients with
bronchiectasis. We have, therefore, performed this
study to evaluate the serum level of TGF-b1 in a
cohort of 95 patients with clinically stable bronch-
iectasis in comparison to 68 healthy control
subjects, and to correlate with clinical parameters.Materials and methods
Subject recruitment
Consecutive patients with proven bronchiectasis
who were not treated with inhaled steroid therapy
and diagnosed by high-resolution computed tomo-graphy (HRCT) were recruited from the specialist
respiratory clinics of the University of Hong Kong
with written informed consent (participation rate
95%). Inclusion criteria included absence of asth-
ma, COPD, tuberculosis, or other unstable systemic
diseases; no alteration in medication and dosage
for at least 3 months; and steady-stable bronch-
iectasis. The latter was defined as the absence of
significant (i.e. o20%) alteration of 24 h sputum
volume, forced expiratory volume in 1 s (FEV1) and
forced vital capacity (FVC), or changes in respira-
tory symptoms for three consecutive weeks.14 All
patients were clinically known as idiopathic
bronchiectasis, which is the most common in Hong
Kong. Out of all patients, there were 14 patients
with antibiotic treatment (1 with clarithromycin,
5 with levofloxacin, 5 with erythromycin, 2 with
gentamycin and 1 with streptomycin). Healthy
control subjects who were receiving no regular
medications and were asymtomatic of respiratory,
cardiovascular, GI, renal, and neurologic diseases
were also recruited randomly from the community
with written informed consent (participation rate
45%). This study had the approval from the Ethics
Committee, Faculty of Medicine, The University of
Hong Kong.Parameters assessed in patients with
bronchiectasis
The bronchiectatic patients were questioned about
the presence of respiratory symptoms, including
cough, dyspnea, haemoptysis, sputum production,
chest pain, and wheezing, and they were examined
physically. The number of lung lobes (including
lingual as an individual lobe) affected by bronch-
iectasis was determined by a thoracic radiologist
who examined the HRCT scan of each patient using
standard criteria.15 Briefly, bronchiectais was pre-
sent when the bronchial segment or sub-segment
appeared larger than the accompanying artery on
HRCT. The volume of a 24-h sputum production was
also determined for each patient as the mean of
three consecutive 24-h collections performed at
steady state. Spirometry (FEV1 and FVC), expressed
as percent predicted, was measured with a
SensorMedics 2200 (Sensor-Medics, Yorba Linda,
USA) package.Blood collection and storage
Clot blood is taken from each subject. Serum was
separated at 1600 g for 10min (4 1C) and stored at
70 1C until assayed for TGF-b1.
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Levels of TGF-b1 in serum were measured using a
commercially available enzyme-linked immunosor-
bent assay (ELISA) kit (BD OptEIATM Set for human
TGF-b1; San Diego, CA, USA) according to the
manufacturer’s instructions. Serum samples were
activated before assay by acidification using 1M
HCl, and diluted with assay buffer bringing TGF-b1
values of all the diluted samples within the linear
range of the standard curve (62.5–4000 pg/ml). The
limit of detection of the assay was 62.5 pg/ml. All
measurements were performed in duplicate. All
samples from patients and controls were measured
in adjacent wells to minimize assay variability. The
reproducibility, calculated as the coefficient of
variation (CV) of intra- and interassay variability,
was 3.5% and 7.5%, respectively.Microbiological assessment of sputum
Fresh sputum was obtained for microbiological
evaluation.16 Standard microbiological procedures
were employed to identify all the sputum bacteria
and classify them into PA and others.Statistical analysis
Data were shown as mean7SD or median (range).
Preliminary inspection of data revealed that serum
TGF-b1 levels were not normally distributed.
Comparisons between groups were made using the
non-parametric Mann–Whitney rank order test.
Correlations were evaluated by Spearman’s rank
method. A P value of o0.05 was taken as
statistically significant. The analysis was performed
using the statistical software (SPSS version 11.0;
SPSS; Chicago, IL, USA).Table 1 Characteristics of study subjects.
N
Male:female
Age (yrs)
Smokers
FEV1% predicted

FVC % predicted
FEV1/FVC

Median 24-h sputum volume (range, ml)
No. of bronchiectatic segments
Median total white blood cell count ( 106/ml)
***Po0.001 obtained by comparing data between healthy contro
Data are presented as mean7SD unless otherwise indicated.Results
Control subjects and patients
Table 1 shows subject demography and clinical
features. There was significant difference between
age (Po0:001) and gender (Po0:001) in the two
groups. Patients with bronchiectasis were signifi-
cantly older, and more women than control
subjects. Of the patients with bronchiectasis, 19
patients were either ex- or current smokers, 26 and
10 patients had colonization with potential patho-
genic microorganisms such as PA or Haemophilus
influenza (HI), respectively, in their sputum. There
was only one patient colonized with Mycobacterium
chelonae in the sputum. Other patients had found
colonization with non-potential pathogenic micro-
organisms such as commensals in their sputum.
Twenty-five control subjects were also either ex- or
current smokers in this study.Serum TGF-b1 levels
Patients with bronchiectasis showed a significantly
higher level of serum TGF-b1 than control subjects
(median [range], 1812.5pg/ml [1226.4–4144.5pg/ml]
vs. 1342.4 pg/ml [940.3–2371.7 pg/ml]; Po0:001)
(Fig. 1). There was no significant difference in
serum TGF-b1 levels among nonsmokers and smo-
kers in either control subjects (1163.5 pg/ml
[993.3–2177.9 pg/ml] vs. 1654.3 pg/ml [905.6–
2414.8 pg/ml] for nonsmokers and smokers, respec-
tively) or patients with stable bronchiectasis
(1845.5 pg/ml [1241.0–3977.4 pg/ml] vs. 1446.5 pg/
ml and [1196.3–4525.7 pg/ml] for nonsmokers
and smokers, respectively). There was also no
significant difference in serum TGF-b1 levels be-
tween stable bronchiectais patients with PA or HIHealthy controls Patients with bronchiectasis
68 95
45:23 32:63***
48.9712.8 58.9714.1***
25 19
Not done 74.3729.1
Not done 84.0723.0
Not done 67.5715.5
N/A 10 (5–25)
N/A 3.071.6
N/A 6.5 (4.9–8.0)
ls and patients with stable bronchiectasis.
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Figure 1 Serum TGF-b1 levels in healthy controls
(n ¼ 68) and patients with stable bronchiectasis
(n ¼ 94). Median (interquartile range) is shown.
***Po0:001:
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Figure 2 Serum TGF-b1 levels in stable bronchiectatic
patients without P. aeruginosa (- PA) or H. influenzae
(HI) colonization (n ¼ 58) and with PA (+PA) or HI (+HI)
colonization (n ¼ 36). Median (interquartile range) is
shown. No significant difference between the two groups
was found.
Table 2 Relationship between serum TGF-b1 with
clinical parameters in patients with stable bronch-
iectasis.
Variables Serum TGF-
b1 (pg/ml)
24-h sputum volume, r (P value) 0.02 (0.87)
No. of bronchiectatic segments,
r (P value)
0.12 (0.27)
FEV1% predicted, r (P value) 0.07 (0.52)
FVC % predicted, r (P value) 0.06 (0.61)
FEV1/FVC, r (P value) 0.08 (0.43)
Total white blood cell count, r
(P value)
0.139 (0.20)
J.C.W. Mak et al.1226colonization (1672.0 pg/ml [1200.7–4780.5 pg/ml])
compared with those without PA or HI colonization
(2069.3 pg/ml [1261.8–3750.6 pg/ml]) (Fig. 2).
Furthermore, patients with or without taking
antibiotics showed similar levels of serum TGF-b1
levels (1965.8 pg/ml [1192.6–3996.3 pg/ml] for
patients with antibiotics [n ¼ 14] vs. 1765.8 pg/ml
[1230.5–4525.7 pg/ml] for patients without anti-
biotics [n ¼ 79]; P40:05).Relationship between TGF-b1 level and
clinically important parameters
Table 2 depicts the correlations between serum
TGF-b1 level with clinical parameters in patients
with stable bronchiectasis. There was no correla-
tion between serum TGF-b1 level with FEV1 (%
predicted), FVC (% predicted), 24-h sputum vo-
lume, and the number of bronchiectatic lung lobes
(P40:05). Correlation analysis between serum
TGF-b1 level and sputum viscosity, sputum puru-
lence, white blood cell count or last exacerbation
frequency also found no significant relationship
(P40:05). However, correlation analysis showed
that 24-h sputum volume correlated positively with
number of lung segments affected by bronchiecta-
sis (r ¼ 0:23; Po0:05), and negatively with FEV1
or FVC (r ¼ 0:25; Po0:05 or r ¼ 0:31; Po0:01;
respectively).Discussion
In this study, we found that the serum TGF-b1 level
was significantly higher in Chinese patients with
bronchiectasis than in control subjects after ad-
justing for differences in age and gender between
groups as the controls were younger and less
women compared with the patients. Moreover, no
difference in serum TGF-b1 level was detected
among nonsmokers and smokers in either control
subjects or patients with bronchiectasis. We also
found no difference in serum TGF-b1 levels
between bronchiectais patients colonized with PA
or HI compared with those without PA or HI
colonization. Correlation analysis showed that
serum TGF-b1 level did not correlate with clinical
parameters such as FEV1, FVC, 24-h sputum
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lobes.
Bronchiectasis is a very common and largely
idiopathic disease among the Chinese.17 Similar to
cystic fibrosis, there are prominent chronic inflam-
matory and infective elements in the pathogenesis
of bronchiectasis. Although our group has shown
that sputum elastase levels correlate with sputum
production, proinflammatory cytokine expression,
and spirometry in patients with stable bronchiec-
tasis,18 which is consistent with previous report in
BAL,19 objective and convenient markers for the
assessment of disease activity in bronchiectasis are
still lacking. The potential involvement of TGF-b1 in
the airways of asthmatics and subjects with COPD
has been hypothesized by several reports. However,
little is known about the circulating TGF-b1
concentration in bronchiectasis. Because growth
factors are able to modulate the proliferation of
fibroblasts and the synthesis of extracellular matrix
components,20 we put forward the hypothesis that
TGF-b1 may play a role in the pathogenesis of sub-
epithelial fibrosis associated with chronic airway
inflammation in bronchiectasis.
The source of elevated serum TGF-b1 levels in
our bronchiectatic patients has not been assessed
in this study. Chu and co-workers have suggested
that neutrophils isolated from peripheral blood
showed a significant increase in expression of TGF-
b1 mRNA and protein in asthmatic patients com-
pared with healthy controls.21 If this is so, one
might anticipate a close association between TGF-
b1 levels and the neutrophil count. In bronchiecta-
sis, there are reports indicating that significantly
higher neutorphils are present in the lamina propria
of the airways, and in induced sputum.22,23 TGF-b1
has been documented to both recruit and activate
neutrophils and to prolong neutrophil survival.24
Therefore, the bronchial and peripheral induced
sputum neutrophilia documented in bronchiectasis
may associate with elevated serum TGF-b1 levels in
these patients. However, we found no correlation
between the white blood cell count and serum TGF-
b1 level in our patient group. The limitation of our
current study is that the elevated serum TGF-b1
levels may not reflect the local concentrations in
the lungs. Without any correlation between serum
TGF-b1 levels and numbers of lung lobes affected
by bronchiectasis, this suggests that the systemic
reflection is not related to the involved lung area.
Other biological samples such as BAL, induced
sputum and exhaled breath condensate, might be
more appropriate in assessing the localization of
TGF-b1 within the respiratory tract, even though
poor correlations between serum cytokines and BAL
have been found previously.19 In addition, there arepolymorphisms in the promoter and in the coding
region of the TGF-b1 gene (C-509 T and T869C) that
have been shown to be associated with increased
production of TGF-b1.
25,26 However, we have not
genotyped our patients in this current study. The
relationship between increased serum TGF-b1
levels and genotypes or increased circulating
neutrophils in bronchiectatic patients merits
further investigation using a larger cohort.
On the other hand, TGF-b1 has been documented
to be activated by matrix metalloproteinase-9
(MMP-9),27 and may be mediated via MMP-9 induced
proteolytic cleavage of latent TGF-binding protein-
1, resulting in release of TGF-b1.
28 This mechanism
therefore could be a link between elastolysis
induced by MMP-9 and simultaneous production of
fibrosis by activation of TGF-b1. In support of this,
our group has found overexpression of MMP-8 and -9
in the lamina propria of bronchiectatic airways.29
Previous reports have documented that infection
of macrophages with certain viruses, parasites, and
protozoa can induce TGF-b1 production, which has
a suppressive action on the host inflammatory
response as well as an increased expression of
TGF-b1 following airway infection with parainfluen-
za virus in animal studies.30–33 However, we found
no difference in serum TGF-b1 levels between
bronchiectasis patients colonized with PA or HI
compared with those without PA or HI colonization,
in agreement with the finding that antibiotic
treatment had no influence on the elevated serum
TGF-b1 levels in this group of clinically stable
bronchiectasis. The discrepancies might be due to
the microorganisms isolated in our study, in con-
trast to Mycobacteria tuberculosis or Chlamydia
trachomatis.33 There was only one patient colo-
nized with M. chelonae found in the sputum from
this study. Therefore, increased serum TGF-b1
levels in bronchiectasis are not reflected by post-
infective phenomenon that serves to down-regu-
late the host immune response.
In conclusion, the results of our current study
clearly show that Chinese patients with stable
bronchiectasis had evidence of elevated serum
TGF-b1 levels, which probably contributed to the
pathogenesis of this disease. Clearly, the role of
increased serum TGF-b1 levels in bronchiectasis
during stable condition and exacerbation merits
further investigation.Acknowledgements
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